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Figure 1. Differential Processing of Neuropeptide Precursors in Distinct Cell Types
Most neuropeptides are produced from proteins that encode multiple bioactive peptides. The precursors
are cleaved at specific sites by a series of endopeptidases (proprotein convertases) and carboxypepti-
dases to generate the mature forms of the peptides. For some peptides, additional processing enzymes
are required to produce the bioactive forms. Due to differences in the enzyme composition between cells,
the precursors can be cleaved into distinct sets of peptides in various cell types. While antibodies often
cross react with larger and smaller forms of a peptide, mass spectrometry can detect the precise form
present in a biological sample.
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and can readily detect novel peptides
(Hummon et al., 2006). Recently, mass
spectrometry approaches have increased
their sensitivity to allow samples as small
as a single cell to be used, although
isolating the specific cell of interest has
remained problematic (Rubakhin et al.,
2011). Most previous attempts to use
mass spectrometry-based techniques
on cells probed with antibodies have
been hindered by the fixation step per-
formed as part of the immunohistochem-
ical staining. For example, fixation with
paraformaldehyde creates large cross-
linked molecules that interfere with the
ionization processes required for mass
spectrometry. In addition, paraformalde-
hyde reacts with peptides to form Schiff-
bases, altering the peptide’s mass. In932 Chemistry & Biology 19, August 24, 2012this issue ofChemistry & Biology, Neupert
et al. (2012) have solved these problems
by including a heating step in the pres-
ence of chemical reagents that reverse
the paraformaldehyde cross-linking, thus
freeing the bound peptide for subsequent
mass spectrometry measurements.
There are many potential applications
for this technique. By first probing a tissue
with antibodies, the cell type can be iden-
tified and subsequent mass spectrometry
analysis can identify the peptide compo-
nents of that cell. Neupert et al. (2012)
demonstrate this application by using
cells from the American cockroach (Peri-
planeta americana). With appropriate
refinement of the mass spectrometry
approaches, it should be possible to per-
form this analysis on mammalian tissues.
Other sample preparation approachesª2012 Elsevier Ltd All rights reservedcan be combined with these new proto-
cols to collect immunostained cells,
including flow cytometry and laser
capture microdissection. The combi-
nation of immunohistochemical-enabled
cell identification and single cell mass
spectrometry will provide more infor-
mation than either technique alone and
will contribute to a better understand-
ing of the molecular differences among
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Activation/exploitation of biosynthetic pathways for useful metabolites is a major current interest. The
metabolism remodeling approach developed by Craney and colleagues in this issue of (Chemistry & Biology),
in which small molecule probes alter the secondary metabolites produced by streptomycetes, could lead to
discovery of a multitude of novel antibiotics and other drugs.An important observation that emerged
from Streptomyces genome sequencing
projects was that although each straincontains genes that encode 20 or more
potential secondary metabolites, only
a fraction are expressed during fermenta-tion. Such cryptic biosynthetic pathways
promise to deliver a multitude of novel
bioactive compounds with the potential
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Figure 1. Outline of the Metabolism Remodeling by
the Small Molecule Probes ARC2 and Triclosan
This shows competition between fatty acid synthesis and
secondary metabolism in using a common substrate acetyl-
CoA (A) and the preferential flow of acetyl-CoA to secondary
metabolism by partial inhibition of a fatty acid synthesis
enzyme FabI by ARC2 or triclosan (B).
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lines. The activation of these cryptic
pathways is thus a major challenge
of current interest (Brakhage and
Schroeckh, 2011; Chiang et al.,
2011). Consequently, the strategies
for rapid strain improvement will
likely be shifting from improved
expression of well-known, highly
productive, secondary metabolite
fermentations to the expression of
novel and often cryptic secondary
metabolite pathways to solve the
early-stage discovery problems of:
(1) getting some level of expression
of cryptic biosynthetic gene clusters
(awaking the sleeping genes) and
(2) rapidly increasing product yields
to obtain enoughmaterial to charac-
terize chemically and biologically
(early-stage yield enhancement)
(Baltz, 2011).
Promising approaches for the
activation of cryptic silent biosyn-
thetic gene clusters in Strepto-
myces species have recently been
developed. One of these involves
selection for drug resistance muta-
tions, which result in mutated ribo-
somes with altered protein and
ppGpp biosynthesis activities (ribo-
some engineering) (Hosaka et al.,2009). Second is the addition of N-acetyl-
glucosamine to media or deletion of the
dasR gene that encodes an N-acetylglu-
cosamine-responsive regulatory protein
(Rigali et al., 2008). Third is constitutive
overexpression of a pathway-specific
LAL regulator gene (Laureti et al., 2011).
These new approaches enable the dis-
covery of novel and/or poorly understood
antibiotics as represented by piperidamy-
cin and stambomycin. Another intriguing
approach has been developed by Craney
et al., 2012 in this issue of Chemistry &
Biology. The absA locus is pleiotropic
regulator of Streptomyces coelicolor,
which encodes the sensor kinase AbsA1
and response regulator AbsA2. In 2010,
the Nodwell group successfully enhanced
the expression of some secondary meta-
bolic genes by introducing the mutant
absA1 alleles of S. coelicolor into heterol-
ogous streptomycetes, eventually leading
to activation of pulvomycin production
(McKenzie et al., 2010). This approach
could be applied to many of the pleio-
tropic regulators identified genetically in
model organisms.These methods act at the transcription
level (i.e., upregulation of biosynthetic
genes), however perturbation of biosyn-
thesis by modulating, for example, the
supply of precursors is also a promising
approach to enhancing the cell’s
capability to produce antibiotics, termed
metabolic engineering (Olano et al.,
2008). In this issue of the Chemistry &
Biology, Nodwell’s laboratory (Craney
et al., 2012) reports a method to enhance
the yields of secondary metabolites
by modulating fatty acid biosynthesis
using small molecules. This method is
applicable to a wide range of actinomy-
cetes and is potentially scalable to high-
throughput.
S. coelicolor is the best-studied actino-
mycete, due in part to the blue-pigmented
polyketide antibiotic actinorhodin, which
enables visual detection of the antibiotic
production. Furthermore, synthesis of
this compound responds to a wide variety
of internal or external stimuli. Based on
these advantages, the Nodwell group
(Craney et al., 2012) screened a large
number (>30,000) of small molecules,Chemistry & Biology 19, August 24, 2012 ª201seeking candidates that might
‘‘remodel’’ the yields of actinorho-
din. As a result, they found 19
compounds, which caused elevated
or precocious production of actino-
rhodin. Four of the 19 molecules,
ARC2, 3, 4, and 5 (antibiotic remod-
eling compounds [ARCs]) were
further studied, and they found that
(1) ARC2 enhances yields of actino-
rhodin and germicidine at low
concentrations, (2) the ARC2 effect
can be observed in other actinomy-
cetes, suggesting that the molecular
target and mechanism of ARC2 is
conserved in diverse actinomy-
cetes, and (3) several of the most
active molecules are structurally
similar to the known antimicrobial
agent triclosan, an inhibitor of fatty
acid synthesis, and the effect of
ARC2 series are exerted through
the inhibition of the enoyl reductase
activity of FabI, which catalyzes the
final and rate-limiting step in fatty
acid biosynthesis (see Figure 1).
Fatty acid synthesis shares the
precursors acetyl-CoA and malonyl-
CoA with polyketide biosynthesis.
Therefore, ‘‘partial’’ inhibition of
fatty acid synthesis could recruit
those acyl-CoAs preferentially topolyketide biosynthesis. Thus, authors
concluded that the relationship between
polyketide and fatty acid biosynthesis is
a very intimate one and that inhibition of
FabI enoyl reductase is important for their
effects on secondary metabolism. These
notions are summarized in Figure 1.
Such a competition in using a common
substrate is known in polyketides
syntheses by Streptomyces avermitilis.
Vegetable oils are often used in industrial
antibiotic fermentation processes as pref-
erable carbon sources. It is generally
believed that the use of these slowly
metabolized carbon sources can avoid
carbon catabolite repression and
increase yields of antibiotics. Fatty acids
derived from vegetable oils are metabo-
lized via the b-oxidation pathway to
generate acetyl-CoA. Given the findings
by Craney et al. (2012), abundant acetyl-
CoA generated from vegetable oils might
perturb fatty acid metabolisms to redirect
the common substrates to secondary
metabolisms.
Of particular interest in this work is
the fact that the ARC2 series not only2 Elsevier Ltd All rights reserved 933
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it induces two unknown compounds in
Strepotomyces peuceticus that could
not be detected in the absence of
ARC2. Conceivably, the expression levels
of the genes encoding those unknown
compounds are very low (i.e., nearly
silent), so that reinforcement of biosyn-
thetic process by efficient substrate
supply made it possible to detect the
products. The strategy described here
can be applicable to strains in the
absence of genome sequence informa-
tion and could facilitate the discovery
of new metabolites. As predicted theo-
retically, this approach could be
made muchmore forceful by combination
with such transcription-associated ap-
proaches as ribosome engineering,
adding N-acetylglucosamine, or LAL
regulator overexpression.
Although polyketides constitute the
majority of secondary metabolites, ami-934 Chemistry & Biology 19, August 24, 2012noglycoside and non-ribosomal peptides
are also valuable in chemotherapy. Is it
possible to develop similar approaches
for such a class of metabolites to access
the full spectrum of secondary metabo-
lites? The crucial question is why cryptic
genes are silent in the laboratory fer-
mentation conditions. Are the silent
genes expressed under the special yet-
unknown environmental conditions? If
so, do the cryptic secondary metabolites
play an intrinsic biological role(s) for
producing organisms under the special
environmental conditions? What are
such special conditions, if any? The
work by Craney et al. (2012) is clearly
an important step toward addressing
these questions.REFERENCES
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With common bacterial pathogens becoming increasingly resistant to the current therapeutic arsenal, there
is a growing need to utilize alternative strategies when developing new antibacterial drugs. In this issue of
Chemistry & Biology, Smith et al. explore the idea of antivirulence drugs by developing inhibitors of the
type IV secretion system in Brucella.Since the advent of widespread anti-
biotic use, pathogenic bacteria have
been under constant pressure to develop
resistances to commonly used antibi-
otics. The ensuing increase in antibiotic
resistance has outpaced the dwindling
production of new drugs, and this situa-
tion is rapidly endangering public health.
While existing antibiotics inhibit overall
bacterial growth by targeting essential
cellular functions, an emerging alternative
strategy targets bacterial virulence
factors without directly killing cells in the
hopes of avoiding the strong selective
pressures of current antibiotics (reviewed
by Cegelski et al., 2008). Bacterial secre-tion systems are particularly compelling
targets, and indeed, there has been sig-
nificant progress over the last decade in
the development of inhibitors of type III
secretion systems and chaperone-usher
secreted pili (Kauppi et al., 2003, Pinkner
et al., 2006). In this issue of Chemistry &
Biology, Smith et al. (2012) extend upon
their previous research to identify several
novel chemicals that bind and inactivate
the type IV secretion system (T4SS) in
Brucella.
The T4SS is capable of secreting DNA
and/or protein substrates and has impor-
tant roles in both conjugation and bacte-
rial pathogenesis. It is an important viru-lence factor of many notable human
pathogens including Helicobacter pylori,
Legionella pneumophila, Bordetella
pertussis, and Ricksettsai prowazekii,
which cause peptic ulcers, Legionnaires’
disease, whooping cough, and typhus
fever, respectively. T4SS are also utilized
by numerous animal pathogens such as
Brucella abortus and Brucella suis, which
both cause disease in cattle and pigs
but can also cause brucellosis in humans.
The T4SS found in Brucella is closely
related to that of the plant pathogen
Agrobacterium tumefaciens, one of the
best characterized T4SS model systems.
Agrobacterium is widely studied and
